BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 17146289)

  • 1. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2.
    Rousseau A; Nutt CL; Betensky RA; Iafrate AJ; Han M; Ligon KL; Rowitch DH; Louis DN
    J Neuropathol Exp Neurol; 2006 Dec; 65(12):1149-56. PubMed ID: 17146289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.
    Ligon KL; Alberta JA; Kho AT; Weiss J; Kwaan MR; Nutt CL; Louis DN; Stiles CD; Rowitch DH
    J Neuropathol Exp Neurol; 2004 May; 63(5):499-509. PubMed ID: 15198128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors.
    Shukla B; Agarwal S; Suri V; Pathak P; Sharma MC; Gupta D; Sharma BS; Suri A; Halder A; Sarkar C
    Neurol India; 2009; 57(5):559-66. PubMed ID: 19934553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of oligodendrocyte lineage genes in oligodendroglial and astrocytic gliomas.
    Riemenschneider MJ; Koy TH; Reifenberger G
    Acta Neuropathol; 2004 Mar; 107(3):277-82. PubMed ID: 14730454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas.
    Nutt CL; Betensky RA; Brower MA; Batchelor TT; Louis DN; Stemmer-Rachamimov AO
    Clin Cancer Res; 2005 Mar; 11(6):2258-64. PubMed ID: 15788675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of in situ demonstration of 1p loss and p53 overexpression in pathologic diagnosis of oligodendroglial tumors.
    Hirose T; Ishizawa K; Shimada S
    Neuropathology; 2010 Dec; 30(6):586-96. PubMed ID: 20408960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profile of tumors with oligodendroglial morphology: Clinical relevance.
    Geevar T; Pai R; Chacko G; Malepathi K; Patel B; John J; Chacko AG; Balakrishnan R; John S
    Neurol India; 2018; 66(6):1726-1731. PubMed ID: 30504574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative chromatin pattern description in Feulgen-stained nuclei as a diagnostic tool to characterize the oligodendroglial and astroglial components in mixed oligo-astrocytomas.
    Decaestecker C; Lopes BS; Gordower L; Camby I; Cras P; Martin JJ; Kiss R; VandenBerg SR; Salmon I
    J Neuropathol Exp Neurol; 1997 Apr; 56(4):391-402. PubMed ID: 9100670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas.
    Bannykh SI; Stolt CC; Kim J; Perry A; Wegner M
    J Neurooncol; 2006 Jan; 76(2):115-27. PubMed ID: 16205963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular genetic evidence for subtypes of oligoastrocytomas.
    Maintz D; Fiedler K; Koopmann J; Rollbrocker B; Nechev S; Lenartz D; Stangl AP; Louis DN; Schramm J; Wiestler OD; von Deimling A
    J Neuropathol Exp Neurol; 1997 Oct; 56(10):1098-104. PubMed ID: 9329453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification.
    Mokhtari K; Paris S; Aguirre-Cruz L; Privat N; Crinière E; Marie Y; Hauw JJ; Kujas M; Rowitch D; Hoang-Xuan K; Delattre JY; Sanson M
    Neuropathol Appl Neurobiol; 2005 Feb; 31(1):62-9. PubMed ID: 15634232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OLIG2 as a specific marker of oligodendroglial tumour cells.
    Marie Y; Sanson M; Mokhtari K; Leuraud P; Kujas M; Delattre JY; Poirier J; Zalc B; Hoang-Xuan K
    Lancet; 2001 Jul; 358(9278):298-300. PubMed ID: 11498220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status.
    Mellai M; Annovazzi L; Senetta R; Dell'Aglio C; Mazzucco M; Cassoni P; Schiffer D
    J Neurooncol; 2017 Jan; 131(2):213-222. PubMed ID: 27796734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells.
    Bouvier C; Bartoli C; Aguirre-Cruz L; Virard I; Colin C; Fernandez C; Gouvernet J; Figarella-Branger D
    J Neurosurg; 2003 Aug; 99(2):344-50. PubMed ID: 12924709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma.
    Gupta M; Djalilvand A; Brat DJ
    Am J Clin Pathol; 2005 Nov; 124(5):755-68. PubMed ID: 16203285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas.
    Cryan JB; Haidar S; Ramkissoon LA; Bi WL; Knoff DS; Schultz N; Abedalthagafi M; Brown L; Wen PY; Reardon DA; Dunn IF; Folkerth RD; Santagata S; Lindeman NI; Ligon AH; Beroukhim R; Hornick JL; Alexander BM; Ligon KL; Ramkissoon SH
    Oncotarget; 2014 Sep; 5(18):8083-92. PubMed ID: 25257301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic identification of glutamine synthetase as a differential marker for oligodendrogliomas and astrocytomas.
    Zhuang Z; Qi M; Li J; Okamoto H; Xu DS; Iyer RR; Lu J; Yang C; Weil RJ; Vortmeyer A; Lonser RR
    J Neurosurg; 2011 Oct; 115(4):789-95. PubMed ID: 21682567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma.
    Kraus JA; Koopmann J; Kaskel P; Maintz D; Brandner S; Schramm J; Louis DN; Wiestler OD; von Deimling A
    J Neuropathol Exp Neurol; 1995 Jan; 54(1):91-5. PubMed ID: 7815084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predominant expression of OLIG2 over ID2 in oligodendroglial tumors.
    Mikami S; Hirose Y; Yoshida K; Kawase T; Ohnishi A; Nagashima K; Mukai M; Okada Y; Ikeda E
    Virchows Arch; 2007 May; 450(5):575-84. PubMed ID: 17431671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.